Preexisting depression (HR 1.45; 95% CI 1.13-1.86) and cognitive dysfunction (HR 1.27; 95% CI 1.02-1.59) were associated with increased mortality after TAVR, with the highest risk in those with both.
Cohort (n=884)
Yes
Hazard Ratio: 1.45 (95% CI 1.13–1.86)
p-value: p=<0.01
BACKGROUND: Depression and cognitive dysfunction (CD) are not routinely screened for in patients before transcatheter aortic valve replacement (TAVR) and their association with postprocedural outcomes is poorly understood. The objectives of this study are to determine the prevalence of depression and CD in patients with aortic stenosis undergoing TAVR and evaluate their association with mortality and quality of life. METHODS: We analyzed a prospective, multicenter TAVR registry that systematically screened patients for preexisting depression and CD with the Patient Health Questionnaire-2 and Mini-Cog, respectively. The associations with mortality were assessed with Cox proportional hazard models and quality of life (Kansas City Cardiomyopathy Questionnaire and EuroQol visual analogue scale) were evaluated using multivariable ordinal regression models. RESULTS: A total of 884 patients were included; median follow-up was 2.88 years (interquartile range=1.2–3.7). At baseline, depression was observed in 19.6% and CD in 31.8%. In separate models, after adjustment, depression (HR, 1.45 95% CI, 1.13–1.86; P <0.01) and CD (HR, 1.27 95% CI, 1.02–1.59; P =0.04) were each associated with increased mortality. Combining depression and CD into a single model, mortality was greatest among those with both depression and CD (n=62; HR, 2.06 CI, 1.44–2.96; P <0.01). After adjustment, depression was associated with 6.6 (0.3–13.6) points lower on the Kansas City Cardiomyopathy Questionnaire 1-year post-TAVR and 6.7 (0.5–12.7) points lower on the EuroQol visual analogue scale. CD was only associated with lower EuroQol visual analogue scale. CONCLUSIONS: Depression and CD are common in patients that undergo TAVR and are associated with increased mortality and worse quality of life. Depression may be a modifiable therapeutic target to improve outcomes after TAVR.
El‐Sabawi et al. (Fri,) conducted a cohort in Aortic stenosis undergoing TAVR (n=884). Depression and cognitive dysfunction vs. Absence of depression and/or cognitive dysfunction was evaluated on Mortality (HR 1.45, 95% CI 1.13-1.86, p=<0.01). Preexisting depression (HR 1.45; 95% CI 1.13-1.86) and cognitive dysfunction (HR 1.27; 95% CI 1.02-1.59) were associated with increased mortality after TAVR, with the highest risk in those with both.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: